GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » PS Ratio

Eidos Therapeutics (Eidos Therapeutics) PS Ratio : 40,736.67 (As of Apr. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eidos Therapeutics's share price is $122.21. Eidos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $0.00. Hence, Eidos Therapeutics's PS Ratio for today is 40,736.67.

Warning Sign:

Eidos Therapeutics Inc stock PS Ratio (=33666.67) is close to 3-year high of 35000

The historical rank and industry rank for Eidos Therapeutics's PS Ratio or its related term are showing as below:

EIDX' s PS Ratio Range Over the Past 10 Years
Min: 49.78   Med: 70.77   Max: 35000
Current: 33666.67

During the past 4 years, Eidos Therapeutics's highest PS Ratio was 35000.00. The lowest was 49.78. And the median was 70.77.

EIDX's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.98 vs EIDX: 33666.67

Eidos Therapeutics's Revenue per Sharefor the three months ended in Sep. 2020 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Eidos Therapeutics was -99.50% per year.

Back to Basics: PS Ratio


Eidos Therapeutics PS Ratio Historical Data

The historical data trend for Eidos Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics PS Ratio Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
PS Ratio
- - - 80.03

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.72 80.03 68.74 62.21 14,133.33

Competitive Comparison of Eidos Therapeutics's PS Ratio

For the Biotechnology subindustry, Eidos Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eidos Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's PS Ratio falls into.



Eidos Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Eidos Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=122.21/0.003
=40,736.67

Eidos Therapeutics's Share Price of today is $122.21.
Eidos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Eidos Therapeutics  (NAS:EIDX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Eidos Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eidos Therapeutics (Eidos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Executives
Uma Sinha director, officer: Chief Scientific Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle officer: Senior Vice President, Finance 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle officer: Chief Business Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox officer: See Remarks C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen director 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat director, 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu officer: CFO and Secretary C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc. 10 percent owner 421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar director, 10 percent owner, officer: Chief Executive Officer C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Eidos Therapeutics (Eidos Therapeutics) Headlines

From GuruFocus